Skip to content

Dr. Gearóid Tuohy

New research on retinal organoids provide valuable insights on genotype and phenotype correlations in Stargardt disease (STGD1).  

Researchers at the Biosciences Institute, Newcastle University, UK, have reported results from a study on differentiated retinal organoids derived from Stargardt disease patients (STGD1). The… Read More »New research on retinal organoids provide valuable insights on genotype and phenotype correlations in Stargardt disease (STGD1).  

Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

The outcomes of an experimental treatment of “LUMEVOQ” (GS010; lenadogene nolparvovec), for ND4-LHON patients, were presented this month by GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985,… Read More »Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

Research on autosomal dominant retinitis pigmentosa (adRP) has reported a novel RP1 truncating mutation, not previously reported in the literature.  

Researchers at the Eye Centre, Zhejiang University School of Medicine, Hangzhou, China, have reported a novel truncating mutation in the RP1 gene (retinitis pigmentosa 1),… Read More »Research on autosomal dominant retinitis pigmentosa (adRP) has reported a novel RP1 truncating mutation, not previously reported in the literature.  

Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.

A collaboration of 41 international clinical centres that manage patients affected with inherited retinal diseases (IRDs), supported by the US Foundation Fighting Blindness (FFB), have… Read More »Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.

Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa. 

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the European Commission has provided a positive opinion from the European… Read More »Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa.